 |
|
|
|
 |
|
|
| Article 1 to 10 out of 13 concerning BioInvent International AB
|
-
ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody
(06/19/2008)
ThromboGenics NV and BioInvent International AB announced that they have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor ...
-
Genentech invests in BioInvent to develop cardiovascular antibodies
(04/08/2008)
BioInvent has entered a strategic partnership with Genentech. Genentech has invested in BioInvent's proprietary antibody for the potential treatment of cardiovascular diseases, and will help co-develop and commercialise the product.BioInvent's ...
-
BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies
(03/13/2008)
BioInvent International AB (OMXS: BINV) announced that it has signed a deal with Bayer HealthCare related to the discovery and development of antibody products. Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research ...
-
BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
(01/21/2008)
BioInvent International AB and co-development partner ThromboGenics NV announced that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial of the novel anti-cancer agent TB-403. TB-403 is a ...
-
ThromboGenics and BioInvent Publicate Data on a Novel Class of Angiogenesis Inhibitors
(11/05/2007)
Novel anti-PlGF antibody, TB-403, being developed by ThromboGenics and BioInvent for
ThromboGenics NV and co-development partner, BioInvent International, announced the publication of data that highlight for the first time the therapeutic potential of anti-PlGF agents to treat cancer based on research performed at the University of ...
-
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
(09/10/2007)
Decision taken to advance novel, long-acting anticoagulant into Phase II clinical development
BioInvent International AB and co-development partner ThromboGenics NV announced that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of TB-402, which is being developed for the ...
-
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials for Anticoagulant TB-402
(02/14/2007)
ThromboGenics NV and BioInvent International AB announced that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402. TB-402 is a human antibody binding to Factor VIII, ...
-
ThromboGenics and BioInvent Awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme
(01/03/2007)
ThromboGenics NV and BioInvent International AB announced that they have received a Euro 2 million grant from the European Union for the joint development of a new class of anti-angiogenesis agents. The new agents will be based on antibodies against ...
-
BioInvent and Immusol to collaborate on antibody therapeutic for macular degeneration
(04/04/2006)
BioInvent International AB and Immusol, Inc. announced a collaboration for the development of a fully human n-CoDeR® antibody for the treatment of age related macular degeneration (AMD) and other ophthalmic disorders. Macular degeneration is ...
-
BioInvent and Cambridge Antibody Technology sign Licensing Agreement
(06/07/2005)
BioInvent International AB announced that it has entered into a licence agreement with Cambridge Antibody Technology. Under the agreement BioInvent and its partners receive rights to use CAT's antibody phage display patent estate to develop products ...
Additional information
BioInvent International AB
Lund, Sweden
Company
|
|
|
|
|
|
Top
